CommodityCoverage
4 minutes ago
Set to begin shortly, Thiogenesis Therapeutics (TTI.v) will be commencing a multi-country, multi-center trial in France and the Netherlands to evaluate the safety, tolerability, and efficacy of its TTI-0102 as a potential treatment for MELAS, a rare mitochondrial disorder with no approved therapies: